title: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
authors.affiliation: Department of Oncology, Ospedale San Donato, Arezzo, Italy. sergio.bracarda@usl8.toscana.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Bracarda
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Melichar
authors.forename: Sylvie
authors.initials: S
authors.lastname: Négrier
authors.forename: Emilio
authors.initials: E
authors.lastname: Bajetta
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
authors.forename: Vesna
authors.initials: V
authors.lastname: Sneller
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier